Abstract: The present invention provides an in vitro method for detecting immunosuppressive fibroblasts, in particular Cancer Associated Fibroblast (CAFs) in a cancer sample from a subject suffering from cancer, wherein the method comprises detecting ANTXR1+ fibroblasts in the cancer sample from said patient. The invention also concerns an in vitro method for predicting a response of a subject suffering from cancer to an immunotherapy treatment, an immunotherapy treatment for use in the treatment of a cancer in a patient, the use of ANTXR1 as a biomarker for the identification of immunosuppressive fibroblasts, in particular immunosuppressive CAFs, an agent targeting ANTXR1+ fibroblasts for use in the treatment of a cancer in a patient, and a product or kit comprising a) an agent targeting ANTXR1+ fibroblasts and b) an immunotherapy treatment.

Abstract: The present invention provides an in vitro method for selecting a patient affected with a tumor for an immunotherapy treatment or for predicting the response of a subject affected with a tumor to an immunotherapy treatment, wherein the method comprises: (a) detecting DPP4+ CAFs (Cancer Associated Fibroblast), and/or CD73+ CAFs, and/or B7H3+ CAFs, and/or OX40L+ CAFs, and/or JAM2+ CAFs in a cancer sample from said patient; (b) determining the level(s) of DPP4+ CAFs, and/or CD73+ CAFs, and/or B7H3+ CAFs, and/or OX40L+ CAFs, and/or JAM2+ CAFs in said cancer sample, wherein the responsiveness of said patient to an immunotherapy treatment is inversely proportional to the level(s) of DPP4+ CAFs, and/or CD73+ CAFs, and/or B7H3+ CAFs, and/or OX40L+ CAFs, and/or JAM2+ CAFs in the cancer sample; (c) optionally, selecting patients with low level(s) of DPP4+ CAFs, and/or CD73+ CAFs, and/or B7H3+ CAFs, and/or OX40L+ CAFs, and/or JAM2+ CAFs as suitable for an immunotherapy treatment.

Abstract: The present invention relates to the use of MAP3K8 protein to predict clinical outcome of a patient affected with a cancer, in particular ovarian cancer, or to select a patient for a treatment comprising one MEK inhibitor. The invention further relates to a method for monitoring a patient affected with a high-MAP3K8 ovarian cancer (i.e. an ovarian cancer with a high expression and/or activity level of MAP3K8) to a treatment comprising at least one MEK inhibitor. The invention also further relates to a MEK inhibitor for use in the treatment of high-MAP3K8 ovarian cancer and kit that can be used in the methods of the invention.